Compare iShares MSCI Canada (TSX) (EWC) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Canada (TSX) vs Tango Therapeutics Inc. — how do they compare? iShares MSCI Canada (TSX) trades at $59.18 (market cap $7.17B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: iShares MSCI Canada (TSX) is the larger of the two by market cap, and iShares MSCI Canada (TSX) is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Canada (TSX) for 57 Days and Tango Therapeutics Inc. for 0 Days on average.
| EWC | TNGX | |
|---|---|---|
Market Cap | $7.17B | $3.75B |
Volume | 3,409,217 | 9,619,106 |
Sector | Broad Market / Factor | Health |
52-Week High | $62.64 | $32.90 |
52-Week Low | $49.72 | $7.50 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWC trades at $59.91, up 0.77% today, with a bullish technical signal from moving averages but neutral oscillators. The stock faces support at $59 and resistance at $60. Recent news highlights Canada's trade tensions with the U.S. and potential EU associate membership, impacting market sentiment.
Outlook is clouded by trade policy uncertainty, though diversification efforts with India and Europe offer growth avenues. Key risks include U.S. tariff escalations and economic volatility. Analyst sentiment is mixed, balancing geopolitical headwinds against strategic partnerships.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Canada (TSX)
EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
